Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DENTSPLY SIRONA Inc.XRAY · Entity 4448 | Director | April 12, 2024 | April 15, 2024 |
| Gen Digital Inc.GEN · Entity 2098 | Director | September 09, 2026 | September 11, 2026 |
| LAM RESEARCH CORPLRCX · Entity 1467 | Director | June 12, 2026 | June 15, 2026 |
| MACERICH COMAC · Entity 3712 | Director | May 30, 2024 | June 04, 2024 |
| Nutanix, Inc.NTNX · Entity 3296 | Director | December 12, 2025 | December 17, 2025 |
| Option Care Health, Inc.OPCH · Entity 4126 | Director | May 20, 2026 | May 22, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director | January 29, 2009 | January 30, 2009 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DENTSPLY SIRONA Inc.
Report date April 12, 2024 · Filed April 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 53,372.146 |
Reported balance
After 2024-04-12 transaction · row 2
1 source rowRow 2 · 2024-04-12 · Grant · Acquired 72.546 · Balance 53,372.146 F1: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. |
| Phantom Stock (Directors' Deferred Compensation) DDCSEC Table II · derivative / convertible security | Direct | 1,543.4018 |
Reported balance
After 2024-04-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-04-12 · Grant · Acquired 7.8111 · Balance 1,543.4018 F2: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F3: Comprised of phantom stock acquired as a result of accrued dividends. |
| Common StockSEC Table I · non-derivative | IndirectBy The Brandt Family Trust U/a Dtd 06/09/2006 | 5,400 |
Reported balance
Holding disclosure · report date 2024-04-12 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 5,400 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis.
F2: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director.
F3: Comprised of phantom stock acquired as a result of accrued dividends.
Gen Digital Inc.
Report date September 09, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,072 |
Ending reported balance
After 2026-09-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-09 · Grant · Acquired 9,072 · Balance 17,894 F1: Annual non-employee director equity award. The RSUs will vest 100% on the earlier of September 9, 2027, or the next annual meeting, and subject to service through the respective vesting date. Row 2 · 2026-09-09 · Gift · Disposed 8,822 · Balance 9,072 F2: Stock transfer to family trust over which the reporting person has voting power. |
| Common StockSEC Table I · non-derivative | IndirectThe Brandt Family Trust | 78,506 |
Reported balance
After 2026-09-09 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-09-09 · Gift · Acquired 8,822 · Balance 78,506 |
Filing footnotes · ownership attribution and instrument terms
F1: Annual non-employee director equity award. The RSUs will vest 100% on the earlier of September 9, 2027, or the next annual meeting, and subject to service through the respective vesting date.
F2: Stock transfer to family trust over which the reporting person has voting power.
LAM RESEARCH CORP
Report date June 12, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 144,705 |
Last balance in matching sequence
After 2026-06-12 transaction · row 17
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
17 source rowsRow 1 · 2026-06-12 · Sale · Disposed 300 · Balance 198,905 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F2: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $355.39 to $356.02, inclusive F3: The amount reported includes shares subject to unvested restricted stock units. Row 2 · 2026-06-12 · Sale · Disposed 1,393 · Balance 197,512 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F4: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $356.685 to $357.67, inclusive F3: The amount reported includes shares subject to unvested restricted stock units. Row 3 · 2026-06-12 · Sale · Disposed 1,100 · Balance 196,412 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F5: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $357.68 to $358.35, inclusive F3: The amount reported includes shares subject to unvested restricted stock units. Row 4 · 2026-06-12 · Sale · Disposed 3,828 · Balance 192,584 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F6: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $358.73 to $359.54, inclusive F3: The amount reported includes shares subject to unvested restricted stock units. Row 5 · 2026-06-12 · Sale · Disposed 1,906 · Balance 190,678 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F7: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $359.84 to $360.79, inclusive F3: The amount reported includes shares subject to unvested restricted stock units. Row 6 · 2026-06-12 · Sale · Disposed 819 · Balance 189,859 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F8: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $360.85 to $361.83, inclusive F3: The amount reported includes shares subject to unvested restricted stock units. Row 7 · 2026-06-12 · Sale · Disposed 2,708 · Balance 187,151 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F9: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $361.87 to $362.82, inclusive F3: The amount reported includes shares subject to unvested restricted stock units. Row 8 · 2026-06-12 · Sale · Disposed 2,345 · Balance 184,806 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F10: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $363.92 to $363.77, inclusive F3: The amount reported includes shares subject to unvested restricted stock units. Row 9 · 2026-06-12 · Sale · Disposed 2,300 · Balance 182,506 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F11: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $363.92 to $364.85, inclusive F3: The amount reported includes shares subject to unvested restricted stock units. Row 10 · 2026-06-12 · Sale · Disposed 1,200 · Balance 181,306 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F12: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $364.98 to $365.67, inclusive F3: The amount reported includes shares subject to unvested restricted stock units. Row 11 · 2026-06-12 · Sale · Disposed 5,803 · Balance 175,503 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F13: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $366.56 to $367.55, inclusive F3: The amount reported includes shares subject to unvested restricted stock units. Row 12 · 2026-06-12 · Sale · Disposed 4,030 · Balance 171,473 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F14: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $367.62 to $368.49, inclusive F3: The amount reported includes shares subject to unvested restricted stock units. Row 13 · 2026-06-12 · Sale · Disposed 4,198 · Balance 167,275 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F15: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $368.70 to $369.64, inclusive F3: The amount reported includes shares subject to unvested restricted stock units. Row 14 · 2026-06-12 · Sale · Disposed 5,037 · Balance 162,238 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F16: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $369.70 to $370.69, inclusive F3: The amount reported includes shares subject to unvested restricted stock units. Row 15 · 2026-06-12 · Sale · Disposed 8,233 · Balance 154,005 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F17: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $370.70 to $371.59, inclusive F3: The amount reported includes shares subject to unvested restricted stock units. Row 16 · 2026-06-12 · Sale · Disposed 7,700 · Balance 146,305 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F18: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $371.77 to $372.76, inclusive F3: The amount reported includes shares subject to unvested restricted stock units. Row 17 · 2026-06-12 · Sale · Disposed 1,600 · Balance 144,705 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F19: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $372.79 to $373.36, inclusive F3: The amount reported includes shares subject to unvested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
F2: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $355.39 to $356.02, inclusive
F3: The amount reported includes shares subject to unvested restricted stock units.
F4: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $356.685 to $357.67, inclusive
F5: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $357.68 to $358.35, inclusive
F6: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $358.73 to $359.54, inclusive
F7: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $359.84 to $360.79, inclusive
F8: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $360.85 to $361.83, inclusive
F9: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $361.87 to $362.82, inclusive
F10: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $363.92 to $363.77, inclusive
F11: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $363.92 to $364.85, inclusive
F12: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $364.98 to $365.67, inclusive
F13: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $366.56 to $367.55, inclusive
F14: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $367.62 to $368.49, inclusive
F15: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $368.70 to $369.64, inclusive
F16: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $369.70 to $370.69, inclusive
F17: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $370.70 to $371.59, inclusive
F18: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $371.77 to $372.76, inclusive
F19: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $372.79 to $373.36, inclusive
MACERICH CO
Report date May 30, 2024 · Filed June 04, 2024 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 62,978 |
Reported balance
Holding disclosure · report date 2024-05-30 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 62,978 |
Nutanix, Inc.
Report date December 12, 2025 · Filed December 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 6,698 |
Reported balance
After 2025-12-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-12-12 · Grant · Acquired 4,588 · Balance 6,698 F1: Reflects shares that the Reporting Person will receive upon the settlement of restricted stock units ("RSUs"), which will vest in full on the earlier of (i) the day prior to the next annual meeting of the Issuer's shareholders held after the date of grant or (ii) the one-year anniversary of the date of grant, in each case, subject to the Reporting Person continuing to provide service to the Issuer through the applicable vesting date. Each RSU represents a contingent right to receive one share of Issuer's Class A common stock. F2: The amount reported includes 4,588 unvested RSUs, which are issuable into shares of the Issuer's Class A common stock upon vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects shares that the Reporting Person will receive upon the settlement of restricted stock units ("RSUs"), which will vest in full on the earlier of (i) the day prior to the next annual meeting of the Issuer's shareholders held after the date of grant or (ii) the one-year anniversary of the date of grant, in each case, subject to the Reporting Person continuing to provide service to the Issuer through the applicable vesting date. Each RSU represents a contingent right to receive one share of Issuer's Class A common stock.
F2: The amount reported includes 4,588 unvested RSUs, which are issuable into shares of the Issuer's Class A common stock upon vesting.
Option Care Health, Inc.
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,999 |
Ending reported balance
After 2026-05-20 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-20 · Grant · Acquired 8,997 · Balance 19,356 F1: The reporting person received an award of restricted stock units on May 20, 2026, which vest in full on May 20, 2027. The number of restricted stock units granted was calculated to reflect $200,000 of value based on the closing price of the issuer's common stock on May 20, 2026. Row 2 · 2026-05-20 · Grant · Acquired 2,643 · Balance 21,999 F2: The reporting person received restricted stock units on May 20, 2026 in lieu of cash retainer payments, which will vest in full on May 20, 2027. The number of restricted stock units granted was calculated to reflect the amount of cash fees received in the form of restricted stock units based on the closing price of the issuer's common stock on May 20, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person received an award of restricted stock units on May 20, 2026, which vest in full on May 20, 2027. The number of restricted stock units granted was calculated to reflect $200,000 of value based on the closing price of the issuer's common stock on May 20, 2026.
F2: The reporting person received restricted stock units on May 20, 2026 in lieu of cash retainer payments, which will vest in full on May 20, 2027. The number of restricted stock units granted was calculated to reflect the amount of cash fees received in the form of restricted stock units based on the closing price of the issuer's common stock on May 20, 2026.
VERTEX PHARMACEUTICALS INC / MA
Report date January 29, 2009 · Filed January 30, 2009
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2009-01-29 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2009-01-29 · Exercise / conversion · Acquired 20,000 · Balance 20,000 Row 2 · 2009-01-29 · Exercise / conversion · Acquired 7,500 · Balance 27,500 Row 3 · 2009-01-29 · Sale · Disposed 27,500 · Balance 0 F1: Transaction made pursuant to Mr. Brandt's company approved trading plan under Rule 10b5-1. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $13.22 · Expires 2013-05-20 | Direct | 0 |
Reported balance
After 2009-01-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2009-01-29 · Exercise / conversion · Disposed 20,000 · Balance 0 F2: Fully vested. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $9.09 · Expires 2015-05-31 | Direct | 0 |
Reported balance
After 2009-01-29 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2009-01-29 · Exercise / conversion · Disposed 7,500 · Balance 0 F2: Fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Mr. Brandt's company approved trading plan under Rule 10b5-1.
F2: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 07, 2014 Filed Nov 12, 2014 17:51 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | GrantCommon Stock | 2,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001192381-14-000038 · primary_doc.xml · nonDerivative · entry 1 BRANDT ERIC · CIK 0001190639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,830 F1 · balance_after: Amount reported includes shares subject to unvested Restricted Stock Units. Read SEC document |
| November 08, 2013 Filed Nov 12, 2013 17:50 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | GrantCommon Stock | 3,590 | $0.00 | $0.00 |
DisclosureSEC source: 0001192381-13-000015 · primary_doc.xml · nonDerivative · entry 1 BRANDT ERIC · CIK 0001190639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,430 F1 · balance_after: Amount reported includes shares subject to unvested Restricted Stock Units. Read SEC document |
| January 28, 2013 Filed Jan 30, 2013 21:27 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | GrantCommon Stock | 3,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001501289-13-000001 · primary_doc.xml · nonDerivative · entry 1 BRANDT ERIC · CIK 0001190639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,843 F1 · balance_after: Amount reported includes shares subject to unvested Restricted Stock Units. Read SEC document |
| February 03, 2012 Filed Feb 7, 2012 19:10 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | GrantCommon Stock | 3,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001501289-12-000007 · primary_doc.xml · nonDerivative · entry 1 BRANDT ERIC · CIK 0001190639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,010 Read SEC document |
| January 31, 2011 Filed Feb 2, 2011 19:54 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | GrantCommon Stock | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001501289-11-000001 · primary_doc.xml · nonDerivative · entry 1 BRANDT ERIC · CIK 0001190639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,390 Read SEC document |
| November 04, 2010 Filed Nov 8, 2010 20:57 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | GrantCommon Stock | 5,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001501289-10-000008 · primary_doc.xml · nonDerivative · entry 1 BRANDT ERIC · CIK 0001190639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,190 Read SEC document |
| January 29, 2009 Filed Jan 30, 2009 21:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Options · Derivative | 7,500 | $0.00 Strike: $9.09 | $0.00 |
DisclosureSEC source: 0000875320-09-000002 · edgar.xml · derivative · entry 5 BRANDT ERIC · CIK 0001190639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2015-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| January 29, 2009 Filed Jan 30, 2009 21:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Options · Derivative | 20,000 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0000875320-09-000002 · edgar.xml · derivative · entry 4 BRANDT ERIC · CIK 0001190639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2013-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| January 29, 2009 Filed Jan 30, 2009 21:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 27,500 | $33.00 | $907,500.00 |
DisclosureSEC source: 0000875320-09-000002 · edgar.xml · nonDerivative · entry 3 BRANDT ERIC · CIK 0001190639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to Mr. Brandt's company approved trading plan under Rule 10b5-1. Read SEC document |
| January 29, 2009 Filed Jan 30, 2009 21:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,500 | $9.09 | $68,175.00 |
DisclosureSEC source: 0000875320-09-000002 · edgar.xml · nonDerivative · entry 2 BRANDT ERIC · CIK 0001190639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2009 Filed Jan 30, 2009 21:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 20,000 | $13.22 | $264,400.00 |
DisclosureSEC source: 0000875320-09-000002 · edgar.xml · nonDerivative · entry 1 BRANDT ERIC · CIK 0001190639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2008 Filed Jun 2, 2008 20:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $28.40 | $0.00 |
DisclosureSEC source: 0000875320-08-000038 · edgar.xml · derivative · entry 1 BRANDT ERIC · CIK 0001190639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2018-05-31 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan. Fully vested. Read SEC document |
| June 01, 2007 Filed Jun 4, 2007 16:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $29.84 | $0.00 |
DisclosureSEC source: 0000875320-07-000060 · edgar.xml · derivative · entry 1 BRANDT ERIC · CIK 0001190639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2017-05-31 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan. Fully vested. Read SEC document |
| June 01, 2006 Filed Jun 5, 2006 12:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $34.32 | $0.00 |
DisclosureSEC source: 0000875320-06-000055 · edgar.xml · derivative · entry 1 BRANDT ERIC · CIK 0001190639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 20,000 shares Expires 2016-05-31 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan. Fully vested. Read SEC document |
| June 01, 2005 Filed Jun 3, 2005 14:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 10,000 | $0.00 Strike: $13.32 | $0.00 |
DisclosureSEC source: 0000875320-05-000023 · edgar.xml · derivative · entry 1 BRANDT ERIC · CIK 0001190639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 10,000 shares Expires 2015-05-31 F1 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan. Fully vested. Read SEC document |
| June 01, 2004 Filed Jun 2, 2004 14:54 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 7,500 | $0.00 Strike: $9.09 | $0.00 |
DisclosureSEC source: 0000875320-04-000064 · edgar.xml · derivative · entry 1 BRANDT ERIC · CIK 0001190639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 7,500 shares Expires 2014-05-31 F1 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan. Fully vested. Read SEC document |
| June 01, 2003 Filed Jun 3, 2003 18:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 7,500 | $0.00 Strike: $14.46 | $0.00 |
DisclosureSEC source: 0000875320-03-000009 · edgar.xml · derivative · entry 1 BRANDT ERIC · CIK 0001190639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 7,500 shares Expires 2013-05-31 F1 · derivative.exercise_date: Right to buy under the 1996 Stock and Option Plan. Fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.